Top Markets
Coin of the day
Daiichi Sankyo Company, Limited Daiichi Sankyo Company, Limited

Daiichi Sankyo Company, Limited

DSNKY
Kedudukan dalam Saham #660
Daiichi Sankyo Company, Limited researches and develops, manufactures, imports,... Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, markets, and sells pharmaceutical products worldwide. The company offers trastuzumab deruxtecan, an anti-cancer agent and anti-HER2 antibody drug conjugate; mirogabalin for pain treatment; teneligliptin/canagliflozin for type 2 diabetes mellitus treatment; lacosamide anti-epileptic agent; prasugrel, an antiplatelet agent; denosumab for osteoporosis and bone disorders; teneligliptin for type 2 diabetes mellitus treatment; edoxaban, an anticoagulant; esomeprazole for ulcer treatment; memantine for treating Alzheimer's disease; and laninamivir for anti-influenza treatment. It also provides olmesartan, an antihypertensive agent; levofloxacin, an antibacterial agent; pravastatin for hypercholesterolemia treatment; and loxoprofen, an anti-inflammatory analgesic. In addition, the company offers colesevelam for treating hypercholesterolemia and type 2 diabetes mellitus treatment; and ferric carboxymaltose and iron sucrose injections for treating anemia. Further, it provides Lulu, a combination cold remedy; Loxonin S, an antipyretic analgesic /anti-inflammatory analgesic; Transino for melasma improvement and treating against spots and freckles; Minon, a skincare product; and Breath Labo and Clean Dental oral care products, as well as Silodosin for dysuria; Gefitinib for malignant tumours; Bicalutamide for prostate cancer; and Tamoxifen, an anti-breast cancer agent. Additionally, the company offers adsorbed cell culture-derived influenza, influenza HA, measles rubella combined, and mumps vaccines. It also provides pharmaceuticals and drugs for animals, cosmetics, medical equipment, food products, drinking water, active pharmaceutical ingredients, and intermediates. It has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. The company was founded in 1899 and is headquartered in Tokyo, Japan.
Harga Saham
$17.64
Modal Pasaran
$32.65B
Perubahan (1 hari)
-3.24%
Perubahan (1 tahun)
-23.70%
Negara
JP
Perdagangan Daiichi Sankyo Company, Limited (DSNKY)

Kategori

EPS untuk Daiichi Sankyo Company, Limited (DSNKY)
EPS setakat December 2025 TTM: $1.05
Menurut laporan kewangan terkini dan harga saham Daiichi Sankyo Company, Limited, EPS semasa syarikat (TTM) adalah $1.05. Pada akhir tahun 2024, syarikat mempunyai EPS sebanyak $0.69 peningkatan berbanding EPS tahun 2023 iaitu $0.43.
Sejarah EPS untuk Daiichi Sankyo Company, Limited dari 2000 hingga 2026
EPS pada akhir setiap tahun
Tahun EPS Ubah
2026 (TTM) $1.05 1.13%
2025 $1.04 50.41%
2024 $0.69 61.24%
2023 $0.43 49.48%
2022 $0.29 -18.86%
2021 $0.35 -42.73%
2020 $0.62 42.60%
2019 $0.43 51.17%
2018 $0.29 20.23%
2017 $0.24 -32.61%
2016 $0.35 -72.19%
2015 $1.27 354.47%
2014 $0.28 -16.43%
2013 $0.33 464.59%
2012 $0.06 -85.19%
2011 $0.40 88.83%
2010 $0.21 -120.58%
2009 $-1.03 -327.81%
2008 $0.45 48.57%
2007 $0.30 -10.07%
2006 $0.34 -2.73%
2005 $0.35 10.33%
2004 $0.32 47.57%
2003 $0.21 -0.88%
2002 $0.22 -12.99%
2001 $0.25 -18.10%
2000 $0.30 0.00%
EPS untuk syarikat atau pesaing yang serupa
Syarikat EPS Perbezaan EPS Negara
$23.00 2,086.94%
US
$6.60 527.56%
GB
$11.10 955.43%
US
$2.37 125.35%
US
$7.20 584.61%
CH